TOP TEN perturbations for 38725_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38725_s_at
Selected probe(set): 209391_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38725_s_at (209391_at) across 6674 perturbations tested by GENEVESTIGATOR:
c-MYC depletion study 4 (RNAi) / control RNAi transfected HeLa cell sample
Relative Expression (log2-ratio):-1.8119898Number of Samples:3 / 3
| Experimental | c-MYC depletion study 4 (RNAi) |
| HeLa cells were harvested 3 days after c-MYC small interfering RNA transfection. | |
| Control | control RNAi transfected HeLa cell sample |
| HeLa cells were harvested 3 days after LacZ small interfering RNA transfection. |
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):1.7969093Number of Samples:2 / 3
| Experimental | glioma study 16 (BS-149) |
| Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):1.7929268Number of Samples:2 / 2
| Experimental | T-cell activation study 1 |
| CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
| Control | quiescent CD4+ T-cell sample |
| Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample
Relative Expression (log2-ratio):1.7780104Number of Samples:2 / 2
| Experimental | T-cell activation study 3 |
| CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs. | |
| Control | resting CD4 T-lymphocyte (crude fraction) sample |
| Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):1.77174Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-229) |
| Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):1.764308Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):1.6908112Number of Samples:15 / 2
| Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
rheumatoid arthritis study 37 (blood; post-treatment; TCZ; non-responder; IFX; non-responder) / rheumatoid arthritis study 37 (blood; naive)
Relative Expression (log2-ratio):1.655611Number of Samples:4 / 18
| Experimental | rheumatoid arthritis study 37 (blood; post-treatment; TCZ; non-responder; IFX; non-responder) |
| Blood samples derived from patients with rheumatoid arthritis (RA) after treatment with tocilizumab (TCZ) and ifliximab (IFX) and classified as non-responder for both drugs. Samples were obtained at 24 weeks after the initiation of drug treatment. Patients who did not displayed a good response on drug treatment were classified as inadequate responders (non-responders) by European League Against Rheumatism (EULAR) response criteria at 24 weeks after the initiation of drug treatment. tocilizumab ATC code: infliximab ATC code: | |
| Control | rheumatoid arthritis study 37 (blood; naive) |
| Blood samples derived from drug-naive patients with rheumatoid arthritis (RA). Drug-naive patients were not being treated with moderate-to-high doses of corticosteroids, immunosuppressants, or biological agents when entered in to the study. |
memory T-cell activation study 1 / untreated memory CD4 T-cell sample
Relative Expression (log2-ratio):1.5804234Number of Samples:3 / 3
| Experimental | memory T-cell activation study 1 |
| Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs. | |
| Control | untreated memory CD4 T-cell sample |
| Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation. |
pediatric septic shock study 3 (toddler; subclass B) / pediatric septic shock study 3 (toddler; subclass A)
Relative Expression (log2-ratio):-1.5653038Number of Samples:15 / 4
| Experimental | pediatric septic shock study 3 (toddler; subclass B) |
| Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass B. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass B was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass B (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.0 - 21.0), maximum number of organ failures 2 (IQR 2 - 3), and an intermediate mortality rate. A significantly greater proportion of patients in subclass B received hydrocortisone for cardiovascular shock. | |
| Control | pediatric septic shock study 3 (toddler; subclass A) |
| Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. |